This company has been acquired
Ayala Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$11.20m |
| Equity | US$8.16m |
| Total liabilities | US$6.10m |
| Total assets | US$14.26m |
Recent financial health updates
Here's Why Ayala Pharmaceuticals (NASDAQ:AYLA) Must Use Its Cash Wisely
Jul 28
Here's Why We're A Bit Worried About Ayala Pharmaceuticals' (NASDAQ:AYLA) Cash Burn Situation
Mar 19Will Ayala Pharmaceuticals (NASDAQ:AYLA) Spend Its Cash Wisely?
Sep 11We Think Ayala Pharmaceuticals (NASDAQ:AYLA) Needs To Drive Business Growth Carefully
Jun 04Recent updates
Ayala stock rises 12% on FDA fast track status for AL102 for desmoid tumors
Sep 27Ayala Pharma rises on positive data from phase 2/3 trial of AL102 in desmoid tumors
Sep 12Here's Why Ayala Pharmaceuticals (NASDAQ:AYLA) Must Use Its Cash Wisely
Jul 28Here's Why We're A Bit Worried About Ayala Pharmaceuticals' (NASDAQ:AYLA) Cash Burn Situation
Mar 19Will Ayala Pharmaceuticals (NASDAQ:AYLA) Spend Its Cash Wisely?
Sep 11We Think Ayala Pharmaceuticals (NASDAQ:AYLA) Needs To Drive Business Growth Carefully
Jun 04Here's Why We're Not Too Worried About Ayala Pharmaceuticals' (NASDAQ:AYLA) Cash Burn Situation
Feb 19Need To Know: Analysts Are Much More Bullish On Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenues
Nov 20
Financial Position Analysis
Short Term Liabilities: AYLA's short term assets ($13.0M) exceed its short term liabilities ($5.7M).
Long Term Liabilities: AYLA's short term assets ($13.0M) exceed its long term liabilities ($396.0K).
Debt to Equity History and Analysis
Debt Level: AYLA is debt free.
Reducing Debt: AYLA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AYLA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AYLA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 30.5% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/21 13:35 |
| End of Day Share Price | 2023/01/18 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ayala Pharmaceuticals, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maurice Raycroft | Jefferies LLC |
| Ahu Demir | Ladenburg Thalmann & Company |
| Naureen Quibria | Maxim Group |